Opin vísindi

Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer

Skoða venjulega færslu

dc.contributor Háskóli Íslands
dc.contributor University of Iceland
dc.contributor.author Piqué, Laia
dc.contributor.author Martinez de Paz, Alexia
dc.contributor.author Piñeyro, David
dc.contributor.author Martínez-Cardús, Anna
dc.contributor.author Castro de Moura, Manuel
dc.contributor.author Llinàs-Arias, Pere
dc.contributor.author Setien, Fernando
dc.contributor.author Gomez-Miragaya, Jorge
dc.contributor.author Gonzalez-Suarez, Eva
dc.contributor.author Sigurdsson, Stefan
dc.contributor.author Jónasson, Jón G.
dc.contributor.author Villanueva, Alberto
dc.contributor.author Vidal, August
dc.contributor.author Davalos, Veronica
dc.contributor.author Esteller, Manel
dc.date.accessioned 2020-03-12T11:26:48Z
dc.date.available 2020-03-12T11:26:48Z
dc.date.issued 2019-08-13
dc.identifier.citation Piqué, L., Martinez de Paz, A., Piñeyro, D. et al. Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer. Oncogene 38, 7106–7112 (2019). https://doi.org/10.1038/s41388-019-0936-x
dc.identifier.issn 0950-9232
dc.identifier.issn 1476-5594 (eISSN)
dc.identifier.uri https://hdl.handle.net/20.500.11815/1588
dc.description Publisher's version (útgefin grein).
dc.description.abstract Human tumors show altered patterns of protein isoforms that can be related to the dysregulation of messenger RNA alternative splicing also observed in transformed cells. Although somatic mutations in core spliceosome components and their associated factors have been described in some cases, almost nothing is known about the contribution of distorted epigenetic patterns to aberrant splicing. Herein, we show that the splicing RNA-binding protein CELF2 is targeted by promoter hypermethylation-associated transcriptional silencing in human cancer. Focusing on the context of breast cancer, we also demonstrate that CELF2 restoration has growth-inhibitory effects and that its epigenetic loss induces an aberrant downstream pattern of alternative splicing, affecting key genes in breast cancer biology such as the autophagy factor ULK1 and the apoptotic protein CARD10. Furthermore, the presence of CELF2 hypermethylation in the clinical setting is associated with shorter overall survival of the breast cancer patients carrying this epigenetic lesion.
dc.description.sponsorship We thank CERCA Program/Generalitat de Catalunya for institutional support. This work was supported by the Health Department PERIS-project no. SLT/002/16/00374 and AGAURprojects nos. 2017SGR1080, 2014SGR633, and 2009SGR1315 of the Catalan Government (Generalitat de Catalunya); the Spanish Institute of Health Carlos III (ISCIII) project no. DTS16/00153 and Ministerio de Economía y Competitividad (MINECO) project no. SAF2014–55000-R, co-financed by the European Development Regional Fund, “A way to achieve Europe” ERDF; the Cellex Foundation; and “la Caixa” Banking Foundation (LCF/PR/PR15/ 11100003).
dc.format.extent 7106-7112
dc.language.iso en
dc.publisher Springer Science and Business Media LLC
dc.relation.ispartofseries Oncogene;38(45)
dc.rights info:eu-repo/semantics/openAccess
dc.subject Cancer genomics
dc.subject Prognostic markers
dc.subject Genamengi
dc.subject Erfðafræði
dc.subject Brjóstakrabbamein
dc.title Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer
dc.type info:eu-repo/semantics/article
dcterms.license Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
dc.description.version Peer Reviewed
dc.identifier.journal Oncogene
dc.identifier.doi 10.1038/s41388-019-0936-x
dc.contributor.department Læknadeild (HÍ)
dc.contributor.department Faculty of Medicine (UI)
dc.contributor.department Lífvísindasetur (HÍ)
dc.contributor.department Biomedical Center (UI)
dc.contributor.school Heilbrigðisvísindasvið (HÍ)
dc.contributor.school School of Health Sciences (UI)


Skrár

Þetta verk birtist í eftirfarandi safni/söfnum:

Skoða venjulega færslu